AI assistant
Lupin Ltd — Capital/Financing Update 2025
May 20, 2025
61031_rns_2025-05-20_b570dd48-3193-4546-b7c0-2e4f457f0cd2.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [79 x 93] intentionally omitted <==
May 20, 2025
National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051
BSE Limited
P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001
Symbol: LUPIN
Scrip Code: Equity - 500257
Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and ‘ ’ Disclosure Requirements) Regulations, 2015 ( Listing Regulations ).
Dear Sir/Madam,
We are pleased to enclose a Press Release as regards, use of Honeywell’s Solstice[®] Air (HFO-1234ze cGMP) propellant by the Company, to transform respiratory care through the development of next-generation inhalers.
The same is for your information and dissemination.
Thanking you,
For LUPIN LIMITED AMIT KUMAR GUPTA
Digitally signed by AMIT KUMAR GUPTA DN: c=IN, st=Maharashtra, 2.5.4.20=f72cf02f52d2a7e595b45b84659bdca28c8f26a939bb35835a 169f2a237229a3, postalCode=400705, street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai, pseudonym=d3a468d0d03546efabffd2a7cb7aaaae, title=7875, serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d70287 df6aad1994f0b522fa08a, o=Personal, cn=AMIT KUMAR GUPTA Date: 2025.05.20 11:38:56 +05'30'
AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)
Encl: a/a.
LUPIN LIMITED
Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com
www.lupin.com
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO
BLOOMBERG: LPCIN
Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Mumbai, Delhi, May 20, 2025 : Global pharma major Lupin Limited (Lupin) announced today its plan to use Honeywell’s Solstice® Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions.
Lupin intends to become the first pharmaceutical company in India to use Honeywell’s Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.[1] By investigating the use of this innovative, nonflammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD.
“Lupin’s partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,” said Vinita Gupta, CEO Lupin .
“Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,” said Jeff Dormo, a president in Honeywell’s Energy and Sustainability Solutions business . “By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements.”
The terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin.
References:
Studies conducted by UNEP and American Lung Association https://www.unep.org/news-and-stories/story/how-do-greenhouse-gases-actually-warm-planet https://www.lung.org/getmedia/cfe2481d-1478-4cea-8a77-1ac3eb112e71/what-you-should-know-ways.pdf
About Lupin
Page 1 of 2
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN
REUTERS: LUPIN.BO
BLOOMBERG: LPCIN
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
For further information or queries please contact:
Rajalakshmi Azariah Vice President & Global Head – Corporate Communications, Lupin [email protected]
About Honeywell
Honeywell is an integrated operating company serving a broad range of industries and geographies around the world. Our business is aligned with three powerful megatrends – automation, the future of aviation and energy transition – underpinned by our Honeywell Accelerator operating system and Honeywell Forge IoT platform. As a trusted partner, we help organizations solve the world's toughest, most complex challenges, providing actionable solutions and innovations through our Aerospace Technologies, Industrial Automation, Building Automation and Energy and Sustainability Solutions business segments that help make the world smarter and safer as well as more secure and sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom
Media Contact - Honeywell
Prashanth Balarama
==> picture [499 x 45] intentionally omitted <==
Solstice® is the registered trademark of Honeywell International Inc.
Page 2 of 2